DRC COMP2
Alternative Names: DCR-COMP-2Latest Information Update: 01 Feb 2022
At a glance
- Originator Dicerna Pharmaceuticals
- Developer Alexion AstraZeneca Rare Disease; Dicerna Pharmaceuticals
- Class Hepatoprotectants; Small interfering RNA
- Mechanism of Action Complement activation inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver disorders
Most Recent Events
- 31 Jan 2022 Dicerna pharmaceutical enters into licensing agreement with Alexion AstraZeneca Rare Disease for the development of RNA interference (RNAi) therapies (Dicerna Pharmaceutical pipeline; January 2022)
- 20 Jan 2022 Alexion Pharmaceuticals was acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 20 Jan 2022 Dicerna Pharmaceuticals was acquired by Novo Nordisk